STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences Inc - CSTL STOCK NEWS

Welcome to our dedicated news page for Castle Biosciences (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Castle Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Castle Biosciences's position in the market.

News
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will release its first-quarter financial results on May 2, 2024. A conference call and webcast will be held to discuss the results. Investors can access the webcast via the company's website or phone. International dial-in numbers are also available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings
-
News
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) supports Esophageal Cancer Awareness Month by collaborating with key programs and initiatives to advance research, prevention, and education. The Company partners with Esophageal Cancer Action Network, Gastro Broadcast podcast, and EndoscopyNow to promote awareness and provide holistic support for patients and the GI professional community. Castle's prognostic risk-stratification test, TissueCypher®, aims to predict progression to high-grade dysplasia or esophageal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
-
News
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces its CFO, Frank Stokes, being selected as a Top 25 CFO of Houston for the second consecutive year. Stokes is recognized for his financial leadership and contribution to the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
none
News
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
Rhea-AI Summary
Castle Biosciences, Inc. presents new data at EADO Congress showing DecisionDx-Melanoma and DecisionDx-SCC tests improve clinical decision-making and reduce costs. The tests accurately stratify patients with melanoma and squamous cell carcinoma, guiding treatment plans and reducing unnecessary procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) is set to present at the 23rd Annual Needham Virtual Healthcare Conference, offering a company overview on April 9, 2024. The presentation will be available via live audio webcast on the company's website, with a replay option post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
News
Castle Biosciences Announces Updates to its Board of Directors
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) appoints Rodney Cotton to its board of directors, bringing extensive leadership experience from Roche Diagnostics. Mara G. Aspinall will not stand for re-election. Cotton's background includes financial turnarounds, global healthcare leadership, and COVID-19 response initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
management
News
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) receives the Top Workplaces USA award for the third year in a row, ranking 28th among 370 companies. The company is recognized for its exceptional workplace culture that prioritizes employee empowerment, trust, transparency, and authenticity. The award is attributed to the dedication of Castle's employees and their commitment to improving health through innovative tests that guide patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
News
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
Rhea-AI Summary
Castle Biosciences presents new data at SSO 2024 demonstrating DecisionDx-Melanoma's ability to predict risk of sentinel lymph node positivity in patients with cutaneous melanoma. The test can help identify high-risk patients who may benefit from more intensive treatment pathways, such as sentinel lymph node biopsy and imaging surveillance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
News
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) releases expert consensus guidelines on the use of DecisionDx-SCC test in determining adjuvant radiation therapy for high-risk squamous cell carcinoma patients. The guidelines aim to improve precision in treatment recommendations based on risk assessment and AJCC8 staging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
News
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces new data highlighting the value of its IDgenetix pharmacogenomic (PGx) test in guiding medication recommendations for older adults with mental health conditions. The study shows one-third of medication recommendations were due to drug-drug interactions and lifestyle factors, emphasizing the importance of personalized medication selection in elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
Stock CSTL logo
Castle Biosciences Inc

Nasdaq:CSTL

CSTL Rankings

#2863 Ranked by Market Cap
#4637 Ranked by Stock Gains
N/A Ranked by Dividends

CSTL Stock Data

553.40M
26.64M
4.28%
89.75%
5.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Friendswood

About CSTL

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.